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A B S T R A C T
Trans-diagnostic, domain- or symptom-focused approaches have been heralded as advancing psychiatric re-
search, but relatively few clinical research programmes have been undertaken to leverage their potential. In this
manuscript we describe the approach and protocol for an exploratory study, PRISM (Psychiatric Ratings using
Intermediate Stratiﬁed Markers), that will be conducted to explore the biomarkers in schizophrenia (SZ) and
Alzheimer’s Disease (AD) that may be related to a common symptom, social withdrawal. Patient participants
(N= 72 SZ and N=72 AD study completers), will complete a series of fMRI, EEG, and behavioural paradigms,
as well as contributing blood-derived (e.g. epigenetic) and smartphone data related to social behaviour. Self- as
well as caregiver- and researcher-reported assessments will be provided to characterise social withdrawal.
Normative data will also be collected from a group of healthy controls (N=48 study completers), half of whom
will be matched in terms of age and gender distribution to the SZ and AD group, respectively. Thus we will
explore both diﬀerentiation and cross-diagnostic overlap in the biomarkers associated with diﬀerent levels of
social withdrawal in SZ and AD. In this way we aim to provide a deeper understanding of the biological un-
derpinnings of symptomatology common to both disorders, and provide insights into novel treatment targets and
future drug development approaches.
1. Background
There is a growing acknowledgement that psychiatric and neurode-
generative disorders overlap much more than previously thought, and
indeed, that they may better be described as domains of trans-diagnostic
traits rather than separable categories (Insel and Cuthbert, 2015; Kas
et al., 2007). The ability to precisely link clinical symptoms or char-
acteristics to underlying neurobiology could facilitate the development of
better treatments and treatment approaches, including patient stratiﬁ-
cation. The value of trans-diagnosic approaches has been further em-
phasized by the conclusions from the recent ‘EU Roadmap for Mental
Health in Europe’ (ROAMER) project, involving over 1000 scientists,
patients, families and professional groups from across Europe; the second
priority for mental health research in Europe was a focus on causal
mechanisms of mental disorders, identifying factors underlying co- and
multi-morbidity, and extending research on single disorders to examine
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common psychopathology across disorders (Wykes et al., 2015).
The PRISM consortium (Psychiatric Ratings using Intermediate
Stratiﬁed Markers) aims to conduct a cross-disorder clinical study in-
volving initially two brain disorders, schizophrenia (SZ) and
Alzheimer’s disease (AD), with a focus on a common clinical feature:
social withdrawal. In a second phase of the project we aim to include
participants with other diagnoses (e.g. major depressive disorder
(MDD), a disorder also associated with social withdrawal). Withdrawal
from friends, family, and colleagues, is one of the symptoms that is
particularly burdensome for relatives of those aﬀected by SZ or AD, and
interestingly is one of the earliest signs of disease in both groups of
patients (Reichman and Negron, 2001; Nelis et al., 2011; Cullen et al.,
2011).
We selected these disorders because they share not only social
withdrawal, but also some cognitive deﬁcits (Cohen et al., 2013;
Martinez-Aran and Vieta, 2015; Weintraub et al., 2012), which are
known to contribute to interpersonal behaviour (Bowie et al., 2008).
Deﬁcits in working memory and attention found in drug-naïve and ﬁrst
episode patients with SZ (Fatouros-Bergman et al., 2014; Mesholam-
Gately et al., 2009) are also found in the very early stages of AD, in-
cluding in patients with Mild Cognitive Impairment (Weintraub et al.,
2012). Interestingly these deﬁcits are also among the most recognized
cognitive impairments seen in patients with MDD (McIntyre et al.,
2013). Further, sensory processing - a term that refers to the way the
nervous system receives messages from the senses and turns them into
appropriate motor and behavioural responses - is found to be impaired
in all three disorders at the earliest stage of disease (McIntyre et al.,
2013; Mesholam-Gately et al., 2009; Weintraub et al., 2012) (see also
Kas et al. (in press)).
Cognitive deﬁcits within domains including working memory, at-
tention, and sensory processing are thus similar across diagnostic
groups and may represent trans-diagnostic processing domains related
to social withdrawal. In fact, some data suggest that interpersonal be-
haviour could be predicted by processing speed, attention and working
memory, together with executive functions and depressive and negative
symptoms, with social competence as a mediating factor (Bowie et al.,
2008). A number of studies have shown that loneliness, itself likely to
be linked (although not parsimonious) with social withdrawal, is a risk
factor for cognitive decline (Tilvis et al., 2004; Wilson et al., 2007; Gow
et al., 2007) (see also Porcelli et al., van der Wee et al., this issue).
Loneliness has also been associated with amyloid burden, itself one of
the most promising biomarkers of AD (Donovan et al., 2016), and has
been linked with psychotic sympoms in a recent meta-analysis
(Michalska da Rocha et al., 2018). In assessing the cognitive abilities of
almost 500 birth-cohort individuals at age 11 and age 79, Gow et al.
(2007) found that loneliness was the only social characteristic that
signiﬁcantly predicted cognitive ability at age 79 after controlling for
factors including sex, years of education, social class, and early-life
cognitive ability (at age 11). The link between social withdrawal and
fundamental aspects of cognition have also been established in animal
studies (Schrijver et al., 2004).
A deep and combined cross-disorder investigation of these domains
may lead to signiﬁcant advances in the understanding of the biological
underpinning of these impairments, paving the way for the develop-
ment of novel treatments targeted at both social withdrawal and cog-
nitive deﬁcits in SZ, AD, and MDD. However, we know of no previous
studies that directly compare SZ, AD and MDD and contrast data from
these patient groups within a single study and using shared experi-
mental tools, despite the clinical and cognitive/neuroiological com-
monalities. Thus, even though there is increasing awareness of cross-
disorder overlap in symptomatology and pathophysiology between
psychiatric disorders, and even between psychiatric and neurological
disorders, examples of true cross-diagnostic approaches in the conduct
of research are limited.
Here, we describe the protocol of the clinical PRISM (Psychiatric
Ratings using Intermediate Stratiﬁed Markers) study, that aims to
explore the biological underpinnings of social withdrawal in SZ and AD.
Our conceptual and methodological approach draws heavily on the
Research Domain Criteria (RDoC) framework proposed by the National
Institute of Mental Health (NIMH) (Insel et al., 2010), and the adap-
tations and recommendations formulated in the ROAMER initiative
(Wykes et al., 2015) (see also Kas et al, in this issue). What this en-
capsulates is an approach that aims to identify cross-diagnostic beha-
vioural and neural phenotypes. This phenotype-driven approach is dif-
ferent from the predominant clinical research and treatment
approaches, in which patients with neuropsychiatric disorders are
grouped into non-overlapping diagnostic categories, e.g. 'schizophrenia'
and ‘Alzheimer’s Disease', and are then investigated or treated ac-
cording to their categorical diagnosis. While these diagnostic categories
are suﬃcient to provide the basis for general clinical management, they
might be ‘artiﬁcial’ distinctions that do not describe the underlying
neurobiology that gives rise to individual symptoms or other relevant
aspects of the clinical proﬁle.
The overarching objectives of the PRISM clinical study are:
(1) To establish whether a set of quantiﬁable biological parameters can
cluster and diﬀerentiate SZ and AD patients characterised by dif-
ferent levels of social withdrawal, and,
(2) To identify and validate biological substrates and cognitive pro-
cesses for social withdrawal in SZ and AD, through the use of
quantitative technologies.
In order to address these objectives, SZ and AD patients with dif-
ferent levels of social withdrawal, as well as healthy control partici-
pants, will be selected and compared on an array of cognitive, atten-
tional, and sensory processing assays. As age has well established eﬀects
on many aspects of neural and cognitive function, and the age of SZ and
AD patients will diﬀer signiﬁcantly (with AD patients being older), it is
essential to control for the eﬀects of age on performance of the study
tasks. By collecting age-matched healthy control data we will be better
able to establish which eﬀects are associated with disease or sympto-
mology, rather than simply with the normal eﬀects of aging.
Participants will complete (f)MRI and EEG assessments, as well
behavioural tasks and questionnaires, selected following rigorous re-
view of the literature by expert PRISM consortium members to probe
the neural and behavioural correlates of social withdrawal, and its link
with cognition (see van der Wee et al., Gilmour et al., Porcelli et al., and
Danjou et al., in this issue). ASL (Arterial Spin Labelling) scan data will
be collected to measure blood perfusion of the brain, and DTI (Diﬀusion
Tensor Imaging) and FLAIR (FLuid Attenuation Inversion Recovery)
MRI sequences will provide data about neural white matter, including
white matter integrity and hyperintensities. As measures for social
withdrawal are proxies that diﬀer between cohorts, a single objective
measure of social withdrawal will also be obtained from a smartphone
application (BEHAPP, www.behapp.org; see also below).
The nature of this study, aimed at achieving deep phenotyping
across a number of domains, requires many assessments. However, it is
also constrained by cost and time pressures. Implementing the number,
breath and in some cases the complexity of the tasks in the two patient
populations - in which cognitive process and stamina may be compro-
mised - also has its challenges. Recognising these issues, we have di-
vided assessments over a number of days with the ﬂexibility to allow
assessments scheduled for a particularly day to be carried over to the
next assessment day. Site staﬀ can also, at their discretion, either not
initiate or terminate an assessment if in their opinion the participant is
unable to complete an assessment (e.g. if the participant is fatigued,
cannot comprehend the instructions for a task, or cannot physically
complete a task). We will continuously monitor feasibility of the study
and the quality of our collected data. This could potentially result in
some minor adaptations to the research protocol if problems are ex-
perienced, which will be informative for future researchers in the ﬁeld
of cross-disorder phenotyping.
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2. Methods and study design
2.1. Study design
The study comprises an exploratory study of three groups: 1) pa-
tients with probable AD; 2) patients with SZ; and 3) a healthy control
group, with half approximately matched in age distribution and gender
proportion to the SZ group, and the other half to the AD group.
The study is conducted at three research sites in the Netherlands
(University Medical center Utrecht, VU University Medical center
Amsterdam and Leiden University Medical Center), and two research
sites in Spain (both located in Madrid: Hospital General Universitario
Gregorio Marañón, and Hospital Universitario de La Princesa). Each of
the Dutch sites will conduct scanning at a respective MRI centre (UMC
Utrecht, Spinoza imaging center in Amsterdam, and Leiden UMC)
whilst for Spain, all scanning will be conducted in the same common
MRI centre (Ruber International Hospital), leading to a total of 4 dif-
ferent MRI sites. We aim to recruit roughly the same number of parti-
cipants for each group (SZ, AD or healthy controls) at each of the four
MRI centres, allowing for the greatest control and statistical accounting
of site eﬀects.
2.2. Sample size
A maximum of 216 participants will be enrolled into the study, with
the expectation that approximately 192 will complete the study.
Approximately 160 patient participants (80 SZ, 80 AD) will be enrolled
with the expectation that 144 (72 SZ, 72 AD) will complete the study.
Approximately 56 healthy control participants, with age distributions
and gender proportions similar to the (younger) SZ and (older) AD
group, will be recruited, with the expectation that up to 48 healthy
controls (24 younger, 24 older) will complete the study.
A formal sample size calculation is challenging because of the
number and variety of outcome measures being explored and the
scarcity of previous research on social withdrawal. This makes the es-
timation of eﬀect sizes for this group comparison particularly diﬃcult.
However, based on previous fMRI group-level analyses for a version of
the N-back task (highly similar to the task being used in the current
study), we have conducted power calculations that suggest that 36
participants per group will be suﬃcient to detect signiﬁcant diﬀerences
between groups within our fMRI data, should they exist. Speciﬁcally,
based on N-back fMRI data drawn from a 2-arm Randomised Controlled
Trial (Smith et al., 2017), and using an anatomical left hippocampal
Region of Interest (ROI), two power-calculations were performed using
a 2-sample t-test design. Comparing drug vs. placebo, an eﬀect size of
0.29 was estimated. Comparing remitted depression vs. control parti-
cipants, an eﬀect size of 0.76 was estimated. Assuming a similar Stan-
dard Deviation and a conservative eﬀect size of 0.29 between, for ex-
ample, the socially withdrawn AD and SZ groups in the present study,
30 participants in each group should be suﬃcient to detect group dif-
ferences at 80% power. Therefore, our target sample size (N= 36) per
group should be adequately powered to detect signiﬁcant changes in
brain activation at the standard statistical threshold (p= 0.05). These
power calculations were performed with the software package fMRI-
power (Mumford and Nichols, 2008).
2.3. Study population
Key inclusion and exclusion criteria for each participant group (SZ,
probable AD, and HC) are described in Tables 1 and 2 below. Note that
this does not represent a comprehensive account of all inclusion and
exclusion criteria but, for brevity, captures what we judge to be the
most essential demographic, medical, and procedural criteria.
Several of the inclusion and exclusion criteria merit further com-
ment. Many of the inclusion and exclusion criteria serve the purpose of
ruling out secondary sources of social withdrawal, such as depression
(hence exclusion criterion based on the MINI and QIDS-SR16), extra-
pyramidal symptoms (hence the ESRS criterion among those patients
receiving antipsychotic medication), psychosis (hence the criteria based
on PANSS scores in the SZ group), or other concomitant medical dis-
orders. Additionally, some of these criteria were adopted to follow the
NIMH recommendations on clinical research into negative symptoms
(Kirkpatrick et al., 2006). So, for example, exclusion of SZ patients
demonstrating substantial drug-induced akinesia, depression, or other
factors that are not part of the disease process itself, helps to avoid
confounds associated with ‘secondary’ negative symptoms. Thus, the
current study is designed to better explore the primary negative
symptom of social withdrawal in SZ (i.e. as part of the disease process
itself) and the relationship with cognitive dysfunction.
Although it did not form one of the strict inclusion or exclusion
Table 1
Inclusion and exclusion criteria applied to both the SZ (schizophrenia) and probable AD (Alzheimer’s Disease) patient groups in the PRISM study (top), and healthy
control volunteers (bottom). QIDS-SR16=Quick inventory of Depressive Symptomatology, Self-Rated, 16 item version; MRI=Magnetic Resonance Imaging;
MINI=Mini-International Neuropsychiatric Interview; MMSE=Mini-Mental State Examination; ESRS=Extrapyramidal Symptom Rating Scale; CNS=Central
Nervous System; DSM=Diagnostic and Statistical Manual of Mental Disorders.
Key Inclusion criteria Key Exclusion criteria
Inclusion and Exclusion Criteria applicable to both SZ and probable AD patients
1 Not socially withdrawn due to external circumstances (e.g. lack of access to
transport, e.g. rural location) or comorbid medical disorder or disability (e.g.,
hearing loss, lack of mobility, facial disﬁgurement).
2 Right-handed or ambidexterous
1 Patients with a current DSM-IV diagnosis of MDD as assessed by the MINI, and with
a QIDS-SR16 score of ≥16.
2 Patients with or any other current primary psychiatric diagnosis requiring
intervention other than AD or SZ that in the judgement of the investigator may aﬀect
the patient's ability to complete the study assessments.
3 Chronic alcohol/drug abuse/dependence within previous 3 years.
4 For patients currently taking antipsychotic medication, ≥4 on the global
Parkinsonism item of the ESRS.
5 Has any contraindications for MRI studies
6 Has unstable comorbid somatic disorder with potential CNS sequelae, or, unstable
dose regimen of medication that may aﬀect CNS (i.e not stable for at least 8 weeks)
Inclusion and Exclusion Criteria applicable to healthy control volunteers
1 Men and women, aged 18-45, inclusive (of similar age distribution and gender
proportion to SZ group) or 50-80, inclusive (of similar age distribution and gender
proportion to AD group)
2 Right-handed or ambidextrous
3 Scores approximately average in the MMSE according to their age and years of
education, as compared with normative data (no more than 1 mark below the
average that would be expected).
1 Current, or history of, Axis-I psychiatric disorder as determined by the MINI, or
neurological disease associated with cognitive impairment.
2 > 5 on the QIDS-SR16 (indicative of mild or more severe depression)
3 Is currently, or has ever, required antidepressant or anxiolytic medication, including
benzodiazepines
4 Has within 6 weeks prior to the ﬁrst assessment visit been prescribed a medication
that may aﬀect the CNS
5 Has any contraindications for MRI studies
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criteria in the present study, younger and older healthy controls will, as
far as possible, be recruited from similar geographical locations to those
participants in the SZ and AD groups, respectively (“zip-code
matching”). The intent is to address diﬀerences in objective social en-
gagement data collected via the smartphone application, BEHAPP (e.g.
proximity to number of Wi-Fi access points and Bluetooth devices)
driven by residential location (e.g. urban vs. rural). Recruitment stra-
tegies for HC participants will target the relevant geographical regions.
2.4. Recruitment
Eligible patient participants will partly be identiﬁed via clinical
programs aﬃliated with the participating study sites, during clinical
assessments. Potentially eligible participants will be given a brief oral
description of the study by their treating physician. If they are inter-
ested, the research team will explain the study in detail before ob-
taining informed consent.
SZ and AD participants will also be recruited from patient cohort
registers available to the participating centres. The study will also be
advertised through public engagement events and various media such
as newspapers, posters, ﬂyers, radio, mail-lists, and social media; it is
expected that the majority of healthy control participants will be re-
cruited via this latter route.
2.5. Procedure
Participants will attend the study centre on at least three assessment
days. A simple schematic ﬁgure of the study design is shown in Fig. 1,
below.
The ﬁrst assessment day will include screening, collection of ques-
tionnaire measures, behavioural testing, a blood draw, and optional
installation of a passive smartphone application (BEHAPP) on partici-
pants’ phones. The second and third assessment days will each include
an MRI and EEG neuroimaging session. For each participant, all as-
sessment days will be as far as possible completed within 42 days from
the 1st (screening) assessment visit, at which point collection of
BEHAPP data will also be terminated. Some ﬂexibility will be allowed
on the study duration and the number of assessment visits required; for
example, patient participants may opt to complete EEG and MRI ses-
sions on diﬀerent days. As far as possible the order of study events will
be held constant across participants. All participants will be asked to
complete a short set of follow-up questionnaires at the end of the study
(+42 days), either online or by telephone.
Table 3 below summarizes the key behavioural, neural, and other
assessments that are included in PRISM, together with the key con-
structs that are measured by each form of data or task.
We realize that our assessment protocol is extensive, and there is
limited experience of any similarly burdensome protocol in both patient
groups. Therefore, feasibility of our assessments will be closely mon-
itored and amendments may take place if assessment burden is too
high.
Patient participants (both SZ and probable AD) will be encouraged
to attend all assessment visits with a “study partner”, an individual who
has regular contact with the participant. The aim is to improve the
tolerability of the study for patient participants, and therefore foster
better compliance with study procedures. In addition, study partners
will be asked to rate the participant's degree of social withdrawal (see
'Characterisation of social withdrawal', below) and study partners of
probable AD participants are additionally asked to complete one clin-
ical assessment, the Neuropsychiatric Inventory (Cummings et al.,
1994), to capture third-party information about the patient’s symptom
severity.
Overall trial management and monitoring will be the responsibility
of the study sponsor (University Medical Centre, Utrecht). For more
detailed descriptions of the tasks included, and the rationale for their
inclusion, see van der Wee et al., Gilmour et al., Porcelli et al., and
Danjou et al., in this issue. Note that not all recommended tasks were
included in the ﬁnal study protocol (e.g. the Attentional Network Task),
due to constraints placed on the length of the assessment days to limit
participant burden.
Table 2
PRISM clinical study inclusion and exclusion criteria speciﬁc to patients with schizophrenia and patients with probable Alzheimer’s Disease (AD). MINI=Mini-
International Neuropsychiatric Interview; MMSE=Mini-Mental State Examination; PANSS=Positive and Negative Syndrome Scale; DSM=Diagnostic and
Statistical Manual of Mental Disorders.
Patients with Schizophrenia Probable Alzheimer’s Disease patients
Key Inclusion criteria Key Exclusion criteria Key Inclusion criteria Key Exclusion criteria
1 Age 18 through 45 years.
2 DSM-IV diagnosis of SZ (conﬁrmed on the
MINI) with at least one conﬁrmed
psychotic episode, but maximum 10 years
disease duration since diagnosis.
3 If the patient uses any antipsychotic,
anticholinergic or antidepressant
medication, dosage stable for at least 8
weeks.
1 A score of≥22 on the 7-item PANSS positive
symptom factor. The score of items for
delusions, hallucinatory behaviour,
suspiciousness and unusual thought content
meet the following requirements:
a No more than 2 of the above items have a
score of 4.
b All of the above items score less than 5.
2 In the clinician’s judgment, patients who, for
any reason, are considered to be a danger to
themselves
1 Age 50 through 80 years
2 Probable AD, meeting the
National Institute on Aging and
the Alzheimer’s Association (NIA-
AA) criteria for probable AD.
3 MMSE score 20- 26.
1 Multiple strokes based on
clinical judgement, as
determined by history and/or
imaging results where available.
Fig. 1. Flow diagram of assessment days and main assessment components
within the PRISM study schedule.
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3. Scales, paradigm development, and systems implementation
3.1. Characterisation of social withdrawal
One of our aims in PRISM is to study the relationship between social
withdrawal and cognition in AD and SZ, and search for both overlap
and diﬀerentiation between the diagnostic cohorts based on this con-
struct. We therefore require a study sample for which there is variation
in social withdrawal exhibited by patient participants, and, good
measures to quantify social behaviour. However, well-validated mea-
sures of social withdrawal do not yet exist. Indeed, improved tools to
characterise social withdrawal are considered a valuable output of the
present study. Taking a pragmatic approach, we selected items from the
WHODAS 2.0 (WHODAS 2.0: World Health Organisation Disability
Assessment Schedule 2.0) as our primary assessment of social with-
drawal, given the extensive prior use of the WHODAS in both clinical
(including SZ, AD and MDD) and in general populations; the open ac-
cess availability of multiple language translations; and the short ad-
ministration time, particularly for a single WHODAS domain. Items that
were selected from the WHODAS 2.0 to characterise social withdrawal
comprise of the following: dealing with people you know; maintaining a
friendship; getting along with close people; making new friends; and
joining in community activities.
Two other self-report scales directly related to social behaviour and
perception will be collected: the Social Functioning Scale (Birchwood
et al., 1990) and the De Jong Gierveld Loneliness and Aﬃliation Scale
(de Jong-Gierveld, 1987). Importantly, to explore the validity of par-
ticipant-reported responses we will additionally collect (where pos-
sible) caregiver- and also researcher-rated WHODAS scores. Data har-
vested from the BEHAPP app will also provide objective data related to
social behaviour.
For more information about the selection of social withdrawal as-
sessments in PRISM, see van der Wee et al., in this issue. We ac-
knowledge our intention to examine the relationship between these
measures of social withdrawal at regular intervals throughout the
study, to determine whether there are clues to guide us in ensuring that
the study sample is rich in the dimension of social withdrawal for both
the AD and SZ groups.
3.2. Behavioural tasks
Development of behavioural tasks was primarily the responsibility
of P1vital® Products Ltd. and P1vital® Ltd. The behavioural paradigms
developed included: FERT (Facial Expression Recognition Task, similar
to that described in (Harmer et al., 2013)), DSST (Digit Symbol
Substitution Task, similar to digit symbol coding in (Wechsler, 1997)),
and EEfRT (Eﬀort Expenditure for Rewards Task (Treadway et al.,
2009; Reddy et al., 2015)). Development also included a “scheduler”
which delivers tasks at appropriate times / in the appropriate order,
and a number of self-report questionnaires. All of this is housed within
the online P1vital® ‘ePRO’ system, and therefore tasks are completed
online via a personalised account which researchers create for partici-
pants. The ePRO system is built to high, industry-regulation standards,
and site staﬀ were all provided with training and materials to provide
for standardised data collection procedures across sites. One task, the
‘Conners Continuous Performance Task - III’, was not possible to de-
velop with ePRO due to licensing issues. This behavioural paradigm
was purchased for use in PRISM (MHS® Assessments). A further task,
the Hinting Task (Corcoran et al., 1995), is a pen-and-paper dialogue-
based task and simply required translation into local languages.
3.3. (f)MRI tasks, sequences, and implementation
The PRISM study involves 4 fMRI data collection sites (3 using
Philips Ingenia 3T-scanners and one using a Siemens Prisma 3T-
scanner) in two countries (The Netherlands and Spain). Technical
variations between scanners are a major source of variability when
running multi-centre fMRI studies and can be minimized by careful
optimization of procedures and sequence parameters. For PRISM, a task
force consisting of consortium members and site technicians identiﬁed
the best possible scanning parameters through an iterative optimization
process. The basic BOLD parameters were standardized between the
diﬀerent scanners, with all major parameters being kept the same and
similar advanced shims being performed at all sites. The development
of the DTI and ASL sequences involved further customization of avail-
able sequences to minimize diﬀerences in acquisition parameters whilst
maximizing signal-to-noise ratio for each site. Additionally, the proce-
dures for setting-up individual MRI scans during each session (e.g.
placing ﬁeld of view, labelling plane for ASL) were standardized.
Technical diﬀerences are easily overshadowed by human and cul-
tural variations, which are more diﬃcult to quantify. To minimize
these, the following steps have been taken. All MRI procedures were
standardized and researchers were trained and provided with materials
to administer these in the same way at all sites. A locked-down com-
puter system and identical peripheral response equipment were pro-
vided for task administration. Stimulus sizes were adjusted to occupy
the same visual angle in the scanner at all sites, and time-of-day eﬀects
were minimized by choosing similar times of day for the assessments,
taking into account cultural diﬀerences by using slightly later time slots
in Spain compared to the Netherlands.
Table 3
Summary of key assessments that are included in PRISM, by modality, data type/task, constructs measured, and corresponding assessment visit.
Modality Task Name / data Key construct(s) or measures Visit
MRI T1 structural Neural structure, morphology 2 & 3
MRI Diﬀusion Tensor Imaging White matter integrity, connectivity 3
MRI T2 ‘FLAIR’ White matter hyperintensities 2
MRI Arterial Spin Labelling Cerebral blood perfusion 3
fMRI N-back Working memory 2
fMRI Virtual Morris Water Maze Spatial working memory 3
fMRI Monetary and Social Incentive Delay task Reward anticipation (social / monetary) 2
fMRI & EEG (separately) Resting state Brain activity when not performing explicit task; functional organisation 2
fMRI & EEG (separate) Facial Emotion Processing task Neural response to facial expression: social cognition/sensory processing 3 / 2
EEG Auditory MMN (eyes open / eyes closed) EEG oddball task: sensory processing 2 / 3
EEG Auditory Steady State Response EEG oddball task: sensory processing 2
Behavioural Conners Continuous Performance Task Attention, vigilance, impulsivity 1
Behavioural Eﬀort Expenditure for Rewards Task Eﬀort-based decision-making; anhedonia 1
Behavioural Digit Symbol Substitution Task General cognitive processing 1
Behavioural Facial Emotion Recognition Task Emotional bias 1
Behavioural Hinting Task Higher-order social cognition: mentalising/theory of mind 1
Passive smartphone monitoring Passive smart-phone monitoring (BEHAPP) E.g. proximity to Wi-Fi/Bluetooth devices; geolocation; social activity Days 1-42
Blood Blood sample analyses Including epigenetics analysis 1
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Development of fMRI tasks was the responsibility of P1vital®
Products Ltd. and P1vital® Ltd. This comprised the Facial Emotion
Processing (FEP) task (similar to that described in (Godlewska et al.,
2012)), the Monetary and Social Incentive Delay Task (Rademacher
et al., 2010), and a version of the N-back task, up to 2-back (similar to
that described in (Smith et al., 2017) but informed by previous studies
using this task in AD and MCI populations (Kumar et al., 2017; Migo
et al., 2015; McGeown et al., 2008)).
3.4. EEG tasks and implementation
All EEG cognitive paradigms were developed and deployed to sites
by Biotrial; for further details see Danjou et al., in this issue. In brief,
software development has been performed using an Eprime (v2.010)
environment, and operational qualiﬁcation of the EEG system was
conducted through an internal pilot study. EEG setup was replicated on
similar hardware and distributed to each study site. Study speciﬁc on-
site training was delivered by Biotrial staﬀ to site staﬀ and following
this a ‘dummy’ EEG recording was performed by each site and validated
by Biotrial prior to EEG accreditation.
3.5. BEHAPP smartphone application
The BEHAPP smartphone application provides a remote, un-
obtrusive and objective measure of sociability and social exploration in
a longitudinal daily-life manner (Eskes et al., 2016; www.behapp.org).
BEHAPP passively monitors smartphone activities, including frequency,
duration and diversity of events, such as incoming and outgoing phone
calls (with number encryption), SMS usage, and social media activities
(e.g., WhatsApp and Facebook events). It is important to note that no
content (e.g., from calls or messages) is being collected. In addition,
GPS and Wi-Fi-access points are being sampled in order to, for example,
integrate movement patterns with social density measures. While both
social and non-social measures are being monitored by using these
measures, it is aimed to provide an objective and quantitative measure
of social withdrawal using BeHapp data features as part of the PRISM
project. Data is secured using industry standard security measures (see
also van der Wee et al., in this issue).
Installing and providing data through BEHAPP is optional in this
study. Participants who are willing to contribute BEHAPP data, but who
do not have an Android smartphone, are oﬀered a research phone for
the duration of the study.
3.6. Case Report Form (CRF) and electronic Case Report Form (eCRF)
The PRISM Case Report Form (CRF) captures demographic and
clinical data as well as other information about the details of the as-
sessment days from individual participants. Data is entered into an
electronic Case Report Form (eCRF), supported by commercial
OpenClinica software, to support comprehensive, eﬃcient, and high-
quality data capture, and to allow for more eﬀective cross-site data
monitoring and management. All relevant site staﬀ are provided with
standardised training on the PRISM CRF and eCRF.
4. Data analysis
All data, including MRI and EEG data, will undergo quality checks
to ensure the highest possible data quality. Participant-level endpoints
will then be extracted for MRI (e.g. average brain activity within pre-
deﬁned ROIs and contrasts of interest speciﬁed in each fMRI task;
fractional anisotropy from DTI; fractional perfusion from ASL), EEG
(e.g. latency, amplitude, and spectral components of event-related po-
tentials), and behavioural data.
More traditional, group-based analyses will be completed on this
endpoint data, for example comparing the diﬀerent participant groups
using a 3-way ANOVA design of AD, SZ, and HCs. Study site will be
included as a covariate of no interest, and analyses will also include
covariates for age, gender, and social withdrawal indices. Medication
information will not be entered as a standard covariate (due to expected
variability in type), but will be used in post-hoc sensitivity analyses
where the inﬂuence of medication can be checked. This will allow
analysis of patient classiﬁcation (e.g. SZ vs. AD, or patient groups vs.
HCs) whilst also allowing an exploration of the eﬀects of aging and
medication. This approach will also allow investigation of the inﬂuence
of social withdrawal dimensions (e.g. through WHODAS score, lone-
liness ratings, or sociability information from the BEHAPP app) across
the participant groups.
However, these traditional methods are limited in the extent to
which they can serve the goals of PRISM, which is to explore whether
there is a set of quantiﬁable biological parameters that can cluster and
diﬀerentiate SZ and AD patients, possibly related to the neural or bio-
logical substrates of social withdrawal. This ambitious goal is better
served by novel statistical methods aimed at clustering data.
5. Cluster analysis
Group-level analyses implement comparisons that are based on re-
searcher-deﬁned participant labels. There is growing consensus that
these labels are not ﬁne-grained enough to allow proper investigation of
the heterogeneity typically observed in patient groups. Therefore,
analyses aimed at clustering unlabelled datasets will be performed,
with the aim of obtaining data-driven groups of patients that share a
common feature or set of features (fMRI, EEG, behavioural). These
analyses are based on the hypothesis that multiple underlying neuro-
biological causes can lead to similar behavioural proﬁles, and con-
versely, that various behavioural proﬁles can be the result of similar
underlying neurobiology.
Inputs for the clustering analyses will be the primary endpoints from
the MRI, EEG, and behavioural analyses. For fMRI speciﬁcally, both
ROI-based endpoints and whole-brain data will be used. Medication can
be used to characterise the retrieved subject groupings. In the clustering
analysis, feature selection techniques will pick out those covariates that
best explain the most relevant clinical symptoms or symptom con-
stellations, and will reveal and rank potential predictive and prognostic
biomarkers. A normative modelling approach will be employed, that
focuses on accurately modelling variation in biological measures across
the entire study cohort. This is done using Gaussian process regression
(GPR) to predict a set of biological response variables (e.g. neuroima-
ging data) from a set of clinically relevant covariates (e.g. trait scores)
while providing estimates of predictive conﬁdence for every prediction.
In a second step we use the distribution learned from the normative
modelling approach (using healthy control data collected from this and
prior studies) to make predictions for individual participants to provide
a score quantifying how much each individual subject deviates from the
normative model (‘Normative probability mapping’). Thereby we will
be able to uncover the underlying biophysical mechanisms, guided by
machine learning, and to deﬁne the most relevant quantitative systems
measures that can be used for the identiﬁcation of underlying me-
chanisms of pathophysiology.
6. Summary
This study will use validated neuroimaging, neuropsychological,
and neurophysiological assessments as well as epigenetics to explore
social withdrawal and cognitive deﬁcits in AD and SZ. Healthy control
data will allow exploration of how biomarkers identiﬁed in the patient
groups compare with normative data, and whether there is in-
dependence of identiﬁed biomarkers from the eﬀects of normal aging.
Clustering analysis will aim to reveal data-driven groups of patients that
share a common feature or set of features (fMRI, EEG, behavioural,
and/or self-report). Findings will contribute to the understanding of
common pathophysiological mechanisms that drive symptoms such as
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social withdrawal, potentially revealing novel targets for treatment of
disorders including SZ and AD.
Study Status
Recruitment started in August 2017.
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